Steer clear of these Two Over-beaten Stock Options
Biotech companies Editas Medicine and Sarepta Therapeutics have been facing a series of challenges that have made them less attractive investment options within the sector.
Clinical and regulatory hurdles are a common obstacle for these companies. Sarepta Therapeutics' development of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), has been marked by ongoing complexities and uncertainties surrounding approvals and commercial success [2][3]. Editas Medicine, specialising in gene editing therapies, likely faces similar challenges as indicated by general biotech sector trends [3].
High therapy pricing and market access issues also pose significant challenges. The high costs associated with gene therapies, reaching from hundreds of thousands to millions of dollars per treatment, create substantial access and reimbursement barriers, particularly in cost-sensitive and emerging markets [4]. This reduces the short- to medium-term revenue potential and slows market adoption rates.
Sarepta Therapeutics is also grappling with a potentially deadly side effect of Elevidys. A patient who took Elevidys died from acute liver failure (ALF) in March, despite clinical trials revealing liver problems as a potential side effect [5]. Another patient died from ALF on June 15, sending Sarepta's stock to new lows [6]. The second patient also had a cytomegalovirus (CMV) infection.
Sarepta Therapeutics' stock price has also been impacted by the withdrawal of its application for approval of golodirsen, another DMD drug, due to insufficient data [1]. The company's stock price has been affected further by the failure of its DMD drug, eteplirsen, to win FDA approval for all patients with the disease [1].
Editas Medicine, meanwhile, has no product on the market or any candidates in phase 3 studies [7]. The company abandoned its investigational treatment Reni-Cel due to the lack of a cash-rich partner to help fund development [8]. Editas Medicine's stock has plummeted over the trailing-12-month period [9].
The biotech industry is experiencing mixed performance and stock price declines due to ongoing clinical setbacks and uncertainty in drug development progress [3]. This climate heightens investment risk for companies like Editas and Sarepta, which are reliant on successful clinical outcomes and regulatory approvals.
Sarepta Therapeutics is currently facing a lawsuit from the Securities and Exchange Commission (SEC) over allegations of misleading investors about the progress of its drug development [10]. Editas Medicine is riskier than some comparable peers, despite partnering with Bristol Myers Squibb for one potential therapy [11].
In light of these challenges and recent track records of failures, investors are advised to approach both Editas Medicine and Sarepta Therapeutics with caution. The companies' stocks have seen significant declines over the trailing-12-month period [9][12]. Both companies remain focused on overcoming these obstacles and mitigating risks to ensure the safety and efficacy of their therapies.
- Investing in biotech companies like Editas Medicine and Sarepta Therapeutics requires a keen understanding of the sector's challenges, as high therapy pricing and market access issues, clinical and regulatory hurdles, and potential side effects can pose significant risks.
- Personal finance management, in the context of investing, must consider these risks, as stocks in such companies have seen significant declines over the trailing-12-month period.
- Technology advancements and modern science, such as gene editing therapies, provide opportunities for investing, but also introduce new uncertainties, as evidenced by the ongoing complexities and uncertainties surrounding approvals and commercial success.
- The medical-conditions targeted by these biotech companies, like Duchenne muscular dystrophy, require innovative solutions, but also come with associated risks, such as fatal side effects like acute liver failure.
- Health-and-wellness seekers might also be interested in following the progress of these biotech companies, as the success of their therapies can potentially provide solutions for various medical conditions, but the journey towards genuine results can be long and filled with uncertainties.
